Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
Natalizumab (Nat) is a humanized monoclonal antibody used for the treatment of relapsing multiple sclerosis (MS). Nat inhibits lymphocyte migration via the blood brain barrier (BBB) by blockage of an integrin adhesion molecule, very late antigen 4. During the phase III clinical trials, it was shown...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2014-01-01
|
| Series: | Journal of Central Nervous System Disease |
| Online Access: | https://doi.org/10.4137/JCNSD.S14049 |
| _version_ | 1828488368233644032 |
|---|---|
| author | Robert Hoepner Simon Faissner Anke Salmen Ralf Gold Andrew Chan |
| author_facet | Robert Hoepner Simon Faissner Anke Salmen Ralf Gold Andrew Chan |
| author_sort | Robert Hoepner |
| collection | DOAJ |
| description | Natalizumab (Nat) is a humanized monoclonal antibody used for the treatment of relapsing multiple sclerosis (MS). Nat inhibits lymphocyte migration via the blood brain barrier (BBB) by blockage of an integrin adhesion molecule, very late antigen 4. During the phase III clinical trials, it was shown that Nat reduces disease activity and prevents disability progression. In addition, several smaller studies indicate a positive influence of Nat on cognition, depression, fatigue, and quality of life (Qol). Therapeutic efficacy has to be weighed against the risk of developing potentially fatal progressive multifocal leukoencephalopathy (PML), an opportunistic infection by JC-virus (JCV) with an incidence of 3.4/1000 (95% CI 3.08–3.74) in Nat treated MS patients. In this review article, we will review data on the presumed mechanism of Nat action, clinical and paraclinical efficacy parameters, and adverse drug reactions with a special focus on PML. |
| first_indexed | 2024-12-11T10:07:13Z |
| format | Article |
| id | doaj.art-c3bd82bba7e54a93a5b3045ad0e0ea9a |
| institution | Directory Open Access Journal |
| issn | 1179-5735 |
| language | English |
| last_indexed | 2024-12-11T10:07:13Z |
| publishDate | 2014-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Journal of Central Nervous System Disease |
| spelling | doaj.art-c3bd82bba7e54a93a5b3045ad0e0ea9a2022-12-22T01:11:54ZengSAGE PublishingJournal of Central Nervous System Disease1179-57352014-01-01610.4137/JCNSD.S14049Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple SclerosisRobert Hoepner0Simon Faissner1Anke Salmen2Ralf Gold3Andrew Chan4Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Germany.Natalizumab (Nat) is a humanized monoclonal antibody used for the treatment of relapsing multiple sclerosis (MS). Nat inhibits lymphocyte migration via the blood brain barrier (BBB) by blockage of an integrin adhesion molecule, very late antigen 4. During the phase III clinical trials, it was shown that Nat reduces disease activity and prevents disability progression. In addition, several smaller studies indicate a positive influence of Nat on cognition, depression, fatigue, and quality of life (Qol). Therapeutic efficacy has to be weighed against the risk of developing potentially fatal progressive multifocal leukoencephalopathy (PML), an opportunistic infection by JC-virus (JCV) with an incidence of 3.4/1000 (95% CI 3.08–3.74) in Nat treated MS patients. In this review article, we will review data on the presumed mechanism of Nat action, clinical and paraclinical efficacy parameters, and adverse drug reactions with a special focus on PML.https://doi.org/10.4137/JCNSD.S14049 |
| spellingShingle | Robert Hoepner Simon Faissner Anke Salmen Ralf Gold Andrew Chan Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis Journal of Central Nervous System Disease |
| title | Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis |
| title_full | Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis |
| title_fullStr | Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis |
| title_full_unstemmed | Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis |
| title_short | Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis |
| title_sort | efficacy and side effects of natalizumab therapy in patients with multiple sclerosis |
| url | https://doi.org/10.4137/JCNSD.S14049 |
| work_keys_str_mv | AT roberthoepner efficacyandsideeffectsofnatalizumabtherapyinpatientswithmultiplesclerosis AT simonfaissner efficacyandsideeffectsofnatalizumabtherapyinpatientswithmultiplesclerosis AT ankesalmen efficacyandsideeffectsofnatalizumabtherapyinpatientswithmultiplesclerosis AT ralfgold efficacyandsideeffectsofnatalizumabtherapyinpatientswithmultiplesclerosis AT andrewchan efficacyandsideeffectsofnatalizumabtherapyinpatientswithmultiplesclerosis |